Biogen Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company with commercial products and development programs in neurology, rare disease and immune-mediated conditions. Forms 8-K cover operating and financial results, product-revenue commentary, acquired in-process research and development, upfront and milestone expenses, collaboration and license-agreement costs, material agreements, capital-structure disclosures and clinical or regulatory updates.
Biogen’s proxy and governance filings address board leadership, director matters, executive compensation and annual meeting items. The filing record also documents the company’s common stock registered on The Nasdaq Global Select Market, officer and director transitions, risk-related forward-looking disclosures and transaction communications tied to strategic business development activity.
Minor Lloyd reported acquisition or exercise transactions in this Form 4 filing.
Biogen Inc. director Lloyd Minor received an equity award of 1,505 restricted stock units. These units were granted at no cash cost and increase his direct holdings to 3,875 shares of common stock. The restricted stock units vest on the earlier of the next annual meeting or the June 9, 2026 grant anniversary.
Freire Maria C reported acquisition or exercise transactions in this Form 4 filing.
Biogen director Maria C. Freire received an equity award of 2,005 shares of common stock in the form of restricted stock units. The grant carried no purchase price and represents compensation rather than an open-market trade. Following this award, she directly owns 8,820 shares of Biogen common stock. The restricted stock units vest on the earlier of the next annual meeting or the June 9, 2026 anniversary of the grant date.
Biogen Inc. reported the voting results from its 2026 Annual Meeting of Stockholders held on June 9, 2026. Stockholders voted on the election of directors and other proposals. Director nominees, including Christopher A. Viehbacher and Lloyd Minor, each received substantially more votes "For" than "Against," with notable support such as 121,127,966 votes "For" for Mr. Viehbacher and 121,220,738 votes "For" for Dr. Minor. One proposal received 124,551,887 votes "For" versus 6,627,086 "Against," while another proposal received 114,184,816 votes "For" and 7,454,737 "Against," along with broker non-votes.
Biogen Inc. filed an amended report to update disclosure related to its acquisition of Apellis Pharmaceuticals, Inc. After further analysis, Biogen determined that this merger does not qualify as a “significant” acquisition under Regulation S-X. Because of this, Biogen states that audited financial statements for Apellis and related pro forma financial information are not required. The amendment removes earlier references to incorporating Apellis financials and to a future filing of pro forma data, while confirming that all other information from the original report remains unchanged.
Biogen Inc. ownership amendment: FMR LLC reports beneficial ownership of 16,652,974.82 shares of Common Stock, equal to 11.3% of the class. The filing lists sole voting power of 15,060,090.91 shares and sole dispositive power of 16,652,974.82. The schedule is an amendment signed on 06/04/2026 and references an Exhibit 99 13d-1(k)(1) agreement.
Biogen Inc. completed its acquisition of Apellis Pharmaceuticals, which is now a wholly owned subsidiary. Biogen’s tender offer valued Apellis at $41.00 in cash per share plus one contingent value right (CVR) per share, with each CVR allowing up to an additional $4.00 in cash if specified sales milestones are met. Approximately 105,687,831 Apellis shares, or about 82.4% of outstanding shares, were tendered before closing. The total cash consideration for the offer and merger is about $5.3 billion, funded with cash and a new $2 billion unsecured term loan split into two $1 billion tranches. Apellis’ key products, EMPAVELI and SYFOVRE, generated $689 million in 2025 net product revenue, and Biogen expects the deal to be accretive to its non‑GAAP diluted EPS in 2027 and to support longer‑term earnings growth.
BIOGEN INC ownership filing: FMR LLC reports beneficial ownership of 12,807,541.50 shares of Common Stock, representing 8.7% of the class as of 03/31/2026. The filing is an amendment (Schedule 13G/A) naming Abigail P. Johnson in a related disclosure and references an exhibit identifying the acquiring subsidiary and a power of attorney.
BIOGEN INC. Head of Corporate Development Adam Keeney reported routine equity compensation transactions involving the company’s common stock. On May 1, 2026, 939 restricted stock units were exercised into 939 shares of common stock at a conversion price of $0.00 per share. To cover tax obligations, 455 shares of common stock were disposed of at a price of $187.06 per share as a tax-withholding transaction, not an open-market sale. Following these transactions, Keeney directly owned 6,365 shares of Biogen common stock. The restricted stock units that were exercised were part of an award that vests in three equal yearly installments beginning on the first anniversary of the May 1, 2023 grant date.
Biogen Inc ownership filing: Vanguard Capital Management reports beneficial ownership of 10,989,562 shares of Biogen common stock, representing 7.48% of the class. The filing shows Vanguard has sole voting power for 1,452,145 shares and sole dispositive power for 10,989,562 shares.
The Schedule 13G statement describes holdings across Vanguard business units and notes the reported interests include shares held for Vanguard funds and other managed accounts.
Biogen Inc. reported modestly higher quarterly revenue and stronger profits while outlining a sizable acquisition. For the three months ended March 31, 2026, revenue rose to $2.48 billion from $2.43 billion a year earlier, driven by multiple sclerosis, rare disease and anti-CD20 program revenue.
Net income attributable to Biogen increased to $319.5 million, up from $240.5 million, with diluted EPS improving to $2.15 from $1.64. Operating cash flow strengthened to $645.5 million, supporting a cash and cash equivalents balance of $3.38 billion and total assets of $29.48 billion.
Biogen also agreed to acquire Apellis Pharmaceuticals for $41.00 per share in cash, valuing the deal at about $5.6 billion, plus a contingent value right of up to $4.00 per share tied to SYFOVRE sales. The company plans to fund the purchase with roughly $3.6 billion of existing cash and marketable securities and about $2.0 billion in bank loans, aiming to add two approved immunology and rare disease products to its portfolio.